Figure 1.

In 2012, 88% of British Columbia Drug Treatment Program (BC DTP) patients had either undetectable viremia (<50 copies/mL) or wild-type human immunodeficiency virus (HIV). Individuals with resistance to 2 or more antiretroviral (ARV) drug categories made up <2% of the HIV-positive population engaged in care in BC, down from 12% in 2000. Patients were grouped by the total number of drug resistance categories (nucleoside reverse transcriptase inhibitor, nonnucleoside reverse transcriptase inhibitor, protease inhibitor) observed in genotypes performed in each calendar year. In years where drug resistance was not assessed, patients were assigned the previous year's result. “Suppressed” are patients with undetectable plasma viral load (pVL; <50 copies/mL) throughout the entire year. “Never Genotyped” are ARV-naive persons or ARV-experienced patients with no previous genotypes. Annual Ns are all patients engaged in care in the BC DTP who had 1 or more pVL measurements that year. Estimates of HIV-positive persons not known to the BC DTP, including HIV-positive persons unaware of their serostatus, are not included. Abbreviations: BC, British Columbia; DTP, Drug Treatment Program; HIV, human immunodeficiency virus.